$-0.02
(Market cap
$7 Mln
Recently Viewed
Clear AllMarket cap
$7 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
8.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-7.8 %
ROCE
-- %
Industry P/E
24.57
EV/EBITDA
-0.8
Debt to Equity
0
Book Value
$--
EPS
$-4.8
Face value
--
Shares outstanding
9,359,130
CFO
$-192.73 Mln
EBITDA
$-218.59 Mln
Net Profit
$-253.56 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
| -95.9 | -12.9 | -64.0 | -95.2 | -78.7 | -69.9 | -49.0 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
| -72.1 | 25.7 | -30.7 | -68.9 | -48.7 | 39.7 | -41.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adamis Pharma (ADMP)
|
0.5 | 7.3 | 12.7 | -11.6 | -118.9 | -- | -- | 8.6 |
| 12.4 | 3,993.9 | 3,018.8 | 72.1 | 12.6 | -80 | 56.9 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 187.9 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 73.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 22.4 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.6 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 | |
| 61.4 | 3,667.1 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.0 |
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine... injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California. Read more
Co-Founder, CEO, Pres & Director
Mr. David J. Marguglio
Co-Founder, CEO, Pres & Director
Mr. David J. Marguglio
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Adamis Pharma (ADMP) is $0.49 (NASDAQ) as of 09-Nov-2023 09:30 EDT. Adamis Pharma (ADMP) has given a return of -78.7% in the last 3 years.
Since, TTM earnings of Adamis Pharma (ADMP) is negative, P/E ratio is not available.
The P/B ratio of Adamis Pharma (ADMP) is 8.62 times as on 09-Nov-2023, a 51 premium to its peers’ median range of 5.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.01
|
-0.45
|
|
2021
|
-0.04
|
0.05
|
|
2020
|
-0.92
|
13.02
|
|
2019
|
-0.02
|
0.02
|
|
2018
|
-0.04
|
0.03
|
The 52-week high and low of Adamis Pharma (ADMP) are Rs -- and Rs -- as of 25-Apr-2026.
Adamis Pharma (ADMP) has a market capitalisation of $ 7 Mln as on 09-Nov-2023. As per SEBI classification, it is a company.
Before investing in Adamis Pharma (ADMP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.